Day One Biopharmaceuticals

DAWN

Market cap $1.32B

Day One Biopharmaceuticals is maintained at a "Strong Buy" rating, driven by robust pipeline progress and multiple upcoming catalysts. The company's OJEMDA achieved FDA approval and delivered 172% year-over-year revenue growth in 2025, with label expansion efforts underway in pivotal phase 3 trial. Two novel ADC programs, Emi-Le and DAY-301, target high-value oncology indications, with key clinical data readouts expected in mid- and late 2026.

Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027.

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago.

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif.

Day One Biopharmaceuticals (DAWN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m.

The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SHOO, DAWN and MCHP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 27th, 2026.

SNDK, SHOO, DAWN, EFXT and MCHP have been added to the Zacks Rank #1 (Strong Buy) List on January 27th, 2026.